These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
764 related articles for article (PubMed ID: 22960556)
1. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers? Zardavas D; Fumagalli D; Loi S Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556 [TBL] [Abstract][Full Text] [Related]
2. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Nahta R; O'Regan RM Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425 [TBL] [Abstract][Full Text] [Related]
3. Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Barnett CM Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124 [TBL] [Abstract][Full Text] [Related]
4. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions. Malaguti P; Vari S; Cognetti F; Fabi A Anticancer Res; 2013 Jan; 33(1):21-8. PubMed ID: 23267124 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Araki K; Miyoshi Y Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897 [TBL] [Abstract][Full Text] [Related]
6. [Antihormonal therapy in breast cancer and mTOR inhibitors]. Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994 [TBL] [Abstract][Full Text] [Related]
7. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Carraway H; Hidalgo M Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929 [TBL] [Abstract][Full Text] [Related]
8. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080 [TBL] [Abstract][Full Text] [Related]
9. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Fedele P; Calvani N; Marino A; Orlando L; Schiavone P; Quaranta A; Cinieri S Crit Rev Oncol Hematol; 2012 Nov; 84(2):243-51. PubMed ID: 22494933 [TBL] [Abstract][Full Text] [Related]
10. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Beck JT; Ismail A; Tolomeo C Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641 [TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors in the treatment of breast cancer. Vinayak S; Carlson RW Oncology (Williston Park); 2013 Jan; 27(1):38-44, 46, 48 passim. PubMed ID: 23461041 [TBL] [Abstract][Full Text] [Related]
13. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826 [TBL] [Abstract][Full Text] [Related]
14. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Baselga J Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436 [TBL] [Abstract][Full Text] [Related]
15. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer. Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244 [TBL] [Abstract][Full Text] [Related]
16. Everolimus in the treatment of hormone receptor-positive breast cancer. Chavez-MacGregor M; Gonzalez-Angulo AM Expert Opin Investig Drugs; 2012 Dec; 21(12):1835-43. PubMed ID: 22994502 [TBL] [Abstract][Full Text] [Related]
17. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Keck S; Glencer AC; Rugo HS Future Oncol; 2012 Nov; 8(11):1383-96. PubMed ID: 23148612 [TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR in mantle cell lymphoma: current and future directions. Smith SM Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453 [TBL] [Abstract][Full Text] [Related]
19. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Diaz-Padilla I; Duran I; Clarke BA; Oza AM Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585 [TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Ciruelos Gil EM Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]